2026-2034年被忽視的熱帶疾病全球市場規模、佔有率、趨勢和成長分析報告

被忽視的熱帶疾病 (NTD) 市場預計將從 2025 年的 45.4 億美元成長到 2034 年的 69 億美元，2026 年至 2034 年的複合年成長率為 4.77%。

隨著越來越多的全球衛生舉措致力於在低收入地區防治感染疾病，被忽視的熱帶疾病的全球市場日益受到關注。各國政府、非政府組織和世界衛生組織都在加大對研究、治療和預防計畫的投入。登革熱、利什曼原蟲症和南美錐蟲病等疾病的負擔持續推動對有效治療方法和診斷方法的需求。新的資金籌措機制和夥伴關係正在促進市場發展。

關鍵促進因素包括公眾對疾病認知的提高、流行地區醫療保健服務的擴展以及世界衛生組織的支持。公私合營正在加速藥物研發和分發，而診斷技術和疫苗研究的進步則進一步加強了疾病控制策略。此外，慈善資金和政策架構也鼓勵製藥公司參與被忽視疾病防治計畫。

隨著生物製藥、疫苗和標靶治療的持續創新，未來前景一片光明。加強發展中地區的醫療衛生基礎設施將有助於擴大治療覆蓋範圍。研究機構、政府和製藥公司之間加強合作將推動研發管線的開發。在全球日益關注醫療公平的背景下，被忽視的熱帶疾病市場預計將保持持續成長，並帶來長期的投資機會。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：被忽視的全球熱帶疾病市場：依疾病類型分類

• 市場分析、洞察與預測
• 地中海熱
• 伊波拉病毒感染疾病
• 南美錐蟲病
• 茲卡病毒感染疾病
• 基孔古尼亞
• 其他

第5章：全球被忽視的熱帶疾病市場：依治療方法

• 市場分析、洞察與預測
• 藥物
• 疫苗

第6章：全球被忽視的熱帶疾病市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射藥物

第7章：全球被忽視的熱帶疾病市場：以最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 居家照護
• 專科診所
• 其他

第8章：全球被忽視的熱帶疾病市場：按分銷管道分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 其他

第9章：被忽視的全球熱帶疾病市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Emergent BioSolutions Inc
  • Moderna
  • Valneva SE
  • Johnson & Johnson Services
  • DAIICHI SANKYO COMPANY
  • LIMITED
  • Insud Pharma Group
  • Humanigen Inc
  • Savant HWP Inc
  • Bayer AG
  • Eisai Co. Ltd
  • Oblita Therapeutics
  • GlaxoSmithKline Plc
  • Themis Bioscience GmbH
  • Novartis AG

The Neglected Tropical Diseases Market size is expected to reach USD 6.90 Billion in 2034 from USD 4.54 Billion (2025) growing at a CAGR of 4.77% during 2026-2034.

The global neglected tropical diseases market has gained attention due to increasing global health initiatives aimed at combating infectious diseases in low-income regions. Governments, non-governmental organizations, and international health agencies are investing in research, treatment, and prevention programs. The burden of diseases such as dengue, leishmaniasis, and Chagas disease continues to drive demand for effective therapeutics and diagnostics. Emerging funding mechanisms and partnerships have strengthened market development.

Key drivers include rising disease awareness, expanded healthcare access in endemic regions, and support from global health organizations. Public-private partnerships have accelerated drug development and distribution. Advances in diagnostic technologies and vaccine research have further enhanced disease management strategies. Additionally, philanthropic funding and policy frameworks are encouraging pharmaceutical companies to participate in neglected disease programs.

Future prospects appear positive as innovation in biologics, vaccines, and targeted therapies continues. Strengthening healthcare infrastructure in developing regions will support wider treatment access. Increased collaboration among research institutions, governments, and pharmaceutical firms will drive pipeline development. As global focus on equitable healthcare intensifies, the neglected tropical diseases market is expected to witness sustained growth and long-term investment opportunities.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease Type

• Mediterranean Fever
• Ebola Virus Infection
• Chagas Disease
• Zika Virus Infection
• Chikungunya
• Others

By Treatment

• Drugs
• Vaccine

By Route of Administration

• Oral
• Injectable

By End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

COMPANIES PROFILED

• Emergent BioSolutions Inc, Moderna, Valneva SE, Johnson Johnson Services, DAIICHI SANKYO COMPANY, LIMITED, Insud Pharma Group, Humanigen Inc, Savant HWP Inc, Bayer AG, Eisai Co Ltd, Oblita Therapeutics, GlaxoSmithKline plc, Themis Bioscience GmbH, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease Type
• 4.2. Mediterranean Fever Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Ebola Virus Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Chagas Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Zika Virus Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Chikungunya Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY TREATMENT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment
• 5.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Disease Type
  • 9.2.2 By Treatment
  • 9.2.3 By Route Of Administration
  • 9.2.4 By End User
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Disease Type
  • 9.3.2 By Treatment
  • 9.3.3 By Route Of Administration
  • 9.3.4 By End User
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Disease Type
  • 9.4.2 By Treatment
  • 9.4.3 By Route Of Administration
  • 9.4.4 By End User
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Disease Type
  • 9.5.2 By Treatment
  • 9.5.3 By Route Of Administration
  • 9.5.4 By End User
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Disease Type
  • 9.6.2 By Treatment
  • 9.6.3 By Route Of Administration
  • 9.6.4 By End User
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL NEGLECTED TROPICAL DISEASES INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Emergent BioSolutions Inc
  • 11.2.2 Moderna
  • 11.2.3 Valneva SE
  • 11.2.4 Johnson & Johnson Services
  • 11.2.5 DAIICHI SANKYO COMPANY
  • 11.2.6 LIMITED
  • 11.2.7 Insud Pharma Group
  • 11.2.8 Humanigen Inc
  • 11.2.9 Savant HWP Inc
  • 11.2.10 Bayer AG
  • 11.2.11 Eisai Co. Ltd
  • 11.2.12 Oblita Therapeutics
  • 11.2.13 GlaxoSmithKline Plc
  • 11.2.14 Themis Bioscience GmbH
  • 11.2.15 Novartis AG